Xia Yan, Hu Yun, Ma Jian-Hua
Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214000, Jiangsu Province, China.
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.
World J Diabetes. 2025 Mar 15;16(3):102526. doi: 10.4239/wjd.v16.i3.102526.
Premixed insulin combines two types of insulin in a single injection. This combination streamlines dosing for patients with type 1 or type 2 diabetes, thereby enhancing convenience. However, patients receiving premixed insulin commonly have less satisfactory blood glucose control. The fixed ratio of insulin in these formulations frequently fails to account for the nuanced demands of individualized glucose-lowering therapy. Moreover, local absorption of mixed insulin and potential systemic autoimmune responses may further compromise glycaemic control. The co-formulation of insulin degludec and insulin aspart introduces a new combination of the two insulin types within a single injection, offering a promising solution for mitigating the limitations inherent in premixed insulin.
预混胰岛素在一次注射中结合了两种类型的胰岛素。这种组合简化了1型或2型糖尿病患者的给药方式，从而提高了便利性。然而，接受预混胰岛素治疗的患者血糖控制通常不太理想。这些制剂中胰岛素的固定比例常常无法满足个体化降糖治疗的细微需求。此外，混合胰岛素的局部吸收和潜在的全身自身免疫反应可能会进一步影响血糖控制。德谷胰岛素和门冬胰岛素的共配制在一次注射中引入了两种胰岛素类型的新组合，为减轻预混胰岛素固有的局限性提供了一个有前景的解决方案。
